Bioceres and Union Acquisition Corp. Announce Transfer of Listing to NYSE American

NEW YORK–(BUSINESS WIRE)–Union Acquisition Corp. (NYSE: LTN, “UAC”) and Bioceres, Inc. announced
today that UAC intends to transfer the listing of its ordinary shares
and warrants to the NYSE American LLC (“NYSE American”) from the New
York Stock Exchange (“NYSE”) following completion of its business
combination, which is expected to close on or about March 4, 2019.
Subject to the completion of the business combination and to the
post-business combination entity meeting the initial listing
requirements of NYSE American, UAC intends to transfer the listing of
its ordinary shares and warrants from NYSE to NYSE American the
following day, March 5, 2019. Upon completion of the business
combination, UAC will change its name to Bioceres Crop Solutions Corp.
The ordinary shares and warrants of Bioceres Crop Solutions Corp. will
trade under the proposed symbols “BIOX” and “BIOX WS,” respectively.

About Union Acquisition Corp.

Union Acquisition Corp. is a blank check company organized for the
purpose of effecting a merger, share exchange, asset acquisition, stock
purchase, recapitalization, reorganization, or other similar business
combination with one or more businesses or entities. UAC’s efforts to
identify a prospective target business are not limited to any particular
industry or geographic region, although the Company has focused on
target businesses located in Latin America. The Company is led by Juan
Sartori, Chairman of the Board of the Company and Chairman and founder
of Union Group International Ltd., and Kyle P. Bransfield, Chief
Executive Officer of the Company and Partner of Atlantic-Pacific
Capital, Inc.

About Bioceres

Bioceres is a fully integrated provider of crop productivity solutions,
including seeds, seed traits, seed treatments, biologicals, high-value
adjuvants and fertilizers. Unlike most industry participants that
specialize in a single technology, chemistry, product, condition or
stage of plant development, Bioceres has developed a multi-discipline
and multi-product platform capable of providing solutions throughout the
entire crop cycle, from pre-planting to transportation and storage.
Bioceres’ platform is designed to cost effectively bring high value
technologies to market through an open architecture approach. Bioceres’
headquarters and primary operations are based in Argentina, which is its
key end-market as well as one of the largest markets globally for GM
crops. Through its main operational subsidiary, Rizobacter, the Company
has a growing and significant international presence, particularly in
Brazil and Paraguay. Bioceres leverages its relationship with its
historical shareholders, many of whom are agricultural leaders and key
participants in Bioceres’ end markets, to increase adoption of its
products and technologies.

Bioceres Investment Highlights:

  • Leading position in large and growing agricultural markets with
    favorable industry dynamics, with a focus on biological assets aimed
    at crop protection, nutrition and seeds.
  • Global leader in drought-tolerance technologies, through the HB4
    family of products – the only technology of its type available today
    for soybean production.
  • Through the Rizobacter brand, Bioceres is a world leader in production
    and sale of soybean biologicals, with over 20% global market share in
    inoculants.
  • Extensive distribution & commercial platform with over 700
    distributors globally and sales in 25 different countries.
  • Proven track-record on delivering strong financial results

Forward Looking Statements

This communication includes “forward-looking statements” within the
meaning of the “safe harbor” provisions of the United States Private
Securities Litigation Reform Act of 1995. Forward-looking statements may
be identified by the use of words such as “forecast,” “intend,” “seek,”
“target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,”
“outlook,” and “project” and other similar expressions that predict or
indicate future events or trends or that are not statements of
historical matters. Such forward-looking statements include estimated
financial information. Such forward-looking statements with respect to
revenues, earnings, performance, strategies, prospects and other aspects
of the businesses of UAC, Bioceres or the combined company after
completion of the business combination are based on current expectations
that are subject to known and unknown risks and uncertainties, which
could cause actual results or outcomes to differ materially from
expectations expressed or implied by such forward- looking statements.
These factors include, but are not limited to: (1) the occurrence of any
event, change or other circumstances that could give rise to the
termination of the exchange agreement entered into in connection with
the proposed business combination (the “Exchange Agreement”) and the
proposed business combination contemplated therein; (2) the inability to
complete the transactions contemplated by the Exchange Agreement due to
the failure to obtain approval of the shareholders or other conditions
to closing in the Exchange Agreement; (3) the ability of UAC to meet
applicable NYSE American listing standards; (4) the risk that the
proposed business combination disrupts current plans and operations of
Bioceres as a result of the announcement and consummation of the
transactions described in the Exchange Agreement; (5) the ability to
recognize the anticipated benefits of the proposed business combination,
which may be affected by, among other things, competition, the ability
of the combined company to grow and manage growth profitably, maintain
relationships with customers and suppliers and retain its management and
key employees; (6) costs related to the proposed business combination;
(7) changes in applicable laws or regulations; (8) the possibility that
Bioceres may be adversely affected by other economic, business, and/or
competitive factors; and (9) other risks and uncertainties indicated
from time to time in the definitive registration statement of UAC in
connection with the proposed business combination and the proxy
statement/prospectus contained therein, including those under “Risk
Factors” therein, and other documents filed or to be filed with the SEC
by UAC. Investors are cautioned not to place undue reliance upon any
forward-looking statements, which speak only as of the date made. UAC
and Bioceres undertake no commitment to update or revise the
forward-looking statements, whether as a result of new information,
future events or otherwise. Investors should carry out their own due
diligence in connection with the assumptions contained herein. The
forward-looking statements in this communication speak only as of the
date of this communication. Although UAC may from time to time
voluntarily update its prior forward-looking statements, it disclaims
any commitment to do so whether as a result of new information, future
events, changes in assumptions or otherwise except as required by
applicable securities laws.

Contacts

Kyle P. Bransfield, Chief Executive Officer
Union Acquisition Corp.
+1
212 981 0633
kbransfield@apcap.com

error: Content is protected !!